TENX Tenax Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TENX matters now
Tenax Therapeutics, Inc. (TENX) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.55 with -4.20% on the session and $301.8M in market capitalization; recent performance reads 1-month +4.53% and YTD -1.56%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-15.7M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.5%.
The latest indexable market news headline is "Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes STAAB THOMAS R II filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.73
P/S
0.00
EV/EBITDA
-1.51
DCF Value
$2.35
FCF Yield
-18.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.3%
ROA
-47.0%
ROIC
-53.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-15.7M | $-0.35 |
| Q4 2025 | $0.00 | $-15.5M | $-0.39 |
| FY 2025 | $0.00 | $-52.6M | $-1.34 |
| Q3 2025 | $0.00 | $-15.8M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.67
Target (Median)
$20.00
Target Range
$20.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.97
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.